---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-257368"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2026-06-04T20:05:17+00:00"
generated_at: "2026-06-04T20:06:37.037955+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology stockholders approve 6.5M share increase for equity plan and 2.5M for ESPP at annual meeting

## Summary
- Stockholders approved amendment to 2014 Equity Incentive Plan, increasing authorized shares by 6.5 million.
- Stockholders approved amendment to 2015 ESPP, increasing authorized shares by 2.5 million.
- Elected three Class III directors: Diane Parks, Mary T. Szela, and Michael J. Vasconcelles, M.D. to terms expiring 2029.
- Ratified Ernst & Young as independent auditor for FY2026; 69.4M for, 140.8K against.
- Advisory Say-on-Pay approved (48.8M for, 1.1M against); board set future votes every year.

## SEC filing metadata
- accession: 0001193125-26-257368
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2026-06-04T20:05:17+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/kura-20260604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-257368
- JSON: https://secwatch.observer/filing/0001193125-26-257368.json
- Plain text: https://secwatch.observer/filing/0001193125-26-257368.txt

## Key facts
- Shareholder Votes
  Kura Oncology, Inc. shareholders approved Advisory Indication on Frequency of Stockholder Advisory Votes on Executive Compensation at the 2026-06-04 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Proposal 4. Advisory Indication on Frequency of Stockholder Advisory Votes on Executive Compensation 1 Year 2 Years 3 Years Abstain Broker Non-Votes 48,362,762 54,055 1,586,672 8,677,543 11,097,548
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm
- Shareholder Votes
  Kura Oncology, Inc. shareholders approved Approval of our Amended ESPP at the 2026-06-04 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Proposal 6. Approval of our Amended ESPP For Against Abstain Broker Non-Votes 58,306,174 213,434 161,424 11,097,548
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm
- Shareholder Votes
  Kura Oncology, Inc. shareholders approved Election of Class III Directors at the 2026-06-04 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Proposal 1. Election of Directors Name of Director Elected For Withheld Broker Non-Votes Diane Parks 44,060,724 14,620,308 11,097,548
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm
- Shareholder Votes
  Kura Oncology, Inc. shareholders approved Approval of our Amended 2014 Plan at the 2026-06-04 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Proposal 5. Approval of our Amended 2014 Plan For Against Abstain Broker Non-Votes 48,402,820 10,099,296 178,916 11,097,548
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm
- Shareholder Votes
  Kura Oncology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-04 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Proposal 3. Advisory Vote on Executive Compensation For Against Abstain Broker Non-Votes 48,783,834 1,141,854 8,755,344 11,097,548
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm
- Shareholder Votes
  Kura Oncology, Inc. shareholders approved Ratification of the Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Proposal 2. Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 69,385,497 140,763 252,320 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.